CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria

Phase 2negativeMK-1167Negative
AI Analysis

Summary

Merck has terminated a Phase 2 trial of oral Alzheimer's drug candidate MK-1167, a compound developed with partner Neuphoria.

Clinical Trial Data

Phase

2

Outcome Details

Phase 2 trial terminated

Importance:5/10
Sentiment:
-0.80
Phase 2 terminationAlzheimer's diseasetrial discontinuationpartnership
Related Companies

Read the original article

Published by Endpoints News on July 1, 2026 6:13 PM

Read Original